Dr. Davis has a 35+ year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including the last 20 years at Johnson & Johnson. Hugh is an expert in the early development of innovative biologics, from asset discovery and characterization through IND and BLA regulatory submissions.

Hugh was the VP and Head of the Biologics Development Sciences department in Janssen Biotherapeutics (JBIO), leading a group of up to 200+ scientists in the biophysical characterization of discovery assets. In addition, over the last 5-6 years in JBIO at J&J, Hugh was also the China Biologics Leader. Together with his team, Dr. Davis was instrumental in the development and approval of many biologic therapies at J&J . Following his tenure at J&J, Dr. Davis took the role of Chief Business Officer at Frontage Laboratories, leading the company to a very successful IPO, on the Hong Kong Exchange (HKSE: 1521) .

Dr. Davis holds a Ph.D. degree in Biochemistry from Villanova University and completed post-Doctoral training at Centocor, Inc. where he patented the characterization of the tumor biomarker for ovarian cancer, CA125.